KCT0000178
招募中
未知
A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma
JEIL-KIRIN PHARMACEUTICAL INC.0 个研究点目标入组 100 人待定
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Diseases of the blood and blood -forming organs and certain disorders involving the immune mechanism
- 发起方
- JEIL-KIRIN PHARMACEUTICAL INC.
- 入组人数
- 100
- 状态
- 招募中
- 最后更新
- 7年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •History of documented asthma exacerbations in 12 months and being determined as eosinophilic\-positive.
排除标准
- •Receipt of drugs that affect to clinical trial or judged by the investigator to be inappropriate for this study
结局指标
主要结局
未指定
相似试验
未知
2 期
A phase IIa , double-blind, placebo-controlled dose-ranging study of KHK4563AsthmaJPRN-jRCT2080221534Kyowa Hakko Kirin Co., Ltd.100
进行中（未招募）
1 期
A Phase II, double blind, placebo controlled, dose-ranging study in patients with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.Postherpetic neuralgiaMedDRA version: 7.1 Level: LLT Classification code 10019979EUCTR2005-005863-26-GBTakeda Global Research & Development Centre (Europe) Ltd
进行中（未招募）
不适用
A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.Postherpetic neuralgiaMedDRA version: 7.1Level: LLTClassification code 10019979EUCTR2005-005863-26-DETakeda Europe R&D Centre Ltd400
进行中（未招募）
不适用
A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.EUCTR2005-005863-26-NLTakeda Europe R&D Centre Ltd400
进行中（未招募）
不适用
A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.Postherpetic neuralgiaMedDRA version: 7.1Level: LLTClassification code 10019979EUCTR2005-005863-26-CZTakeda Europe R&D Centre Ltd400